455 related articles for article (PubMed ID: 19073203)
1. Disease-oriented approach to botulinum toxin use.
Jankovic J
Toxicon; 2009 Oct; 54(5):614-23. PubMed ID: 19073203
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.
Sheffield JK; Jankovic J
Expert Rev Neurother; 2007 Jun; 7(6):637-47. PubMed ID: 17563247
[TBL] [Abstract][Full Text] [Related]
3. An update on the use of botulinum toxin therapy in Parkinson's disease.
Mills R; Bahroo L; Pagan F
Curr Neurol Neurosci Rep; 2015 Jan; 15(1):511. PubMed ID: 25407133
[TBL] [Abstract][Full Text] [Related]
4. Botulinum Toxin Therapy for Parkinson's Disease.
Wagle Shukla A; Malaty IA
Semin Neurol; 2017 Apr; 37(2):193-204. PubMed ID: 28511260
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin in the management of parkinsonian disorders.
Grippe T; Chen R
Toxicon; 2023 Aug; 232():107209. PubMed ID: 37429465
[TBL] [Abstract][Full Text] [Related]
6. Dystonic frowning without blepharospasm.
Hirota N; Hirota M; Mezaki T
Parkinsonism Relat Disord; 2008 Nov; 14(7):579-80. PubMed ID: 18316230
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin treatment of secretory disorders.
Naumann M; Jost W
Mov Disord; 2004 Mar; 19 Suppl 8():S137-41. PubMed ID: 15027066
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin treatment in parkinsonism.
Anandan C; Jankovic J
J Neurol Sci; 2024 Jan; 456():122810. PubMed ID: 38056063
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin: from toxin to therapeutic agent.
Behari M; Goyal V
J Assoc Physicians India; 2000 Feb; 48(2):225-33. PubMed ID: 11229154
[No Abstract] [Full Text] [Related]
10. Use of botulinum toxin in Parkinson's disease.
Jocson A; Lew M
Parkinsonism Relat Disord; 2019 Feb; 59():57-64. PubMed ID: 30579818
[TBL] [Abstract][Full Text] [Related]
11. What is new in the era of focal dystonia treatment? Botulinum injections and more.
Cetinkaya A; Brannan PA
Curr Opin Ophthalmol; 2007 Sep; 18(5):424-9. PubMed ID: 17700237
[TBL] [Abstract][Full Text] [Related]
12. Use of Botulinum Neurotoxin in Parkinson's Disease: A Critical Appraisal.
Jost WH
Toxins (Basel); 2021 Jan; 13(2):. PubMed ID: 33503872
[TBL] [Abstract][Full Text] [Related]
13. Botulinum Toxin Treatment of Motor Disorders in Parkinson Disease-A Systematic Review.
Jabbari B; Comtesse SM
Toxins (Basel); 2023 Jan; 15(2):. PubMed ID: 36828396
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin: clinical use.
Truong DD; Jost WH
Parkinsonism Relat Disord; 2006 Sep; 12(6):331-55. PubMed ID: 16870487
[TBL] [Abstract][Full Text] [Related]
15. An update on new and unique uses of botulinum toxin in movement disorders.
Jankovic J
Toxicon; 2018 Jun; 147():84-88. PubMed ID: 28888928
[TBL] [Abstract][Full Text] [Related]
16. Dystonia: medical therapy and botulinum toxin.
Jankovic J
Adv Neurol; 2004; 94():275-86. PubMed ID: 14509685
[No Abstract] [Full Text] [Related]
17. Combination of blepharospasm and apraxia of eyelid opening: a condition resistant to treatment.
Rana AQ; Shah R
Acta Neurol Belg; 2012 Mar; 112(1):95-6. PubMed ID: 22427299
[TBL] [Abstract][Full Text] [Related]
18. New therapeutic indications for botulinum toxins.
Cordivari C; Misra VP; Catania S; Lees AJ
Mov Disord; 2004 Mar; 19 Suppl 8():S157-61. PubMed ID: 15027069
[TBL] [Abstract][Full Text] [Related]
19. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
[TBL] [Abstract][Full Text] [Related]
20. Botulinum A toxin for the so-called apraxia of lid opening.
Lepore V; Defazio G; Acquistapace D; Melpignano C; Pomes L; Lamberti P; Livrea P; Ferrari E
Mov Disord; 1995 Jul; 10(4):525-6. PubMed ID: 7565842
[No Abstract] [Full Text] [Related]
[Next] [New Search]
